SynthesisBMC neurology2010
Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships.
Synthesis in BMC neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pregabalin add-on for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Pregabalin add-on for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2019Pooled it
- Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response.Journal of pharmacokinetics and pharmacodynamics · 2014Pooled it
- Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second.European journal of clinical pharmacology · 2012Pooled it
- Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients.Clinical drug investigation · 2013Trial
- Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers.Psychopharmacology · 2012Trial
- A systematic survey shows that reporting and handling of missing outcome data in networks of interventions is poor.BMC medical research methodology · 2018Article
- Effects of Soluble Corn Fiber Alone or in Synbiotic Combination withFrontiers in immunology · 2017Article
- Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain.Therapeutic advances in drug safety · 2014Review
- Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.Clinical pharmacokinetics · 2014Review
- Gabapentin: An update of its pharmacological properties and therapeutic use in epilepsy.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare the efficacy of pregabalin and gabapentin at comparable effective dose levels in patients with refractory partial epilepsy.
methodsEight randomized placebo controlled trials investigating the efficacy of pregabalin (4 studies) and gabapentin (4 studies) over 12 weeks were identified with a systematic literature search. The endpoints of interest were "responder rate" (where response was defined as at least a 50% reduction from baseline in the number of seizures) and "change from baseline in seizure-free days over the last 28 days (SFD)". Results of all trials were analyzed using an indirect comparison approach with placebo as the common comparator. The base-case analysis used the intention-to-treat last observation carried forward method. Two sensitivity analyses were conducted among completer and responder populations.
resultsThe base-case analysis revealed statistically significant differences in response rate in favor of pregabalin 300 mg versus gabapentin 1200 mg (odds ratio, 1.82; 95% confidence interval, 1.02, 3.25) and pregabalin 600 mg versus gabapentin 1800 mg (odds ratio, 2.52; 95% confidence interval, 1.21, 5.27). Both sensitivity analyses supported the findings of the base-case analysis, although statistical significance was not demonstrated. All dose levels of pregabalin (150 mg to 600 mg) were more efficacious than corresponding dosages of gabapentin (900 mg to 2400 mg) in terms of SFD over the last 28 days.
conclusionIn patients with refractory partial epilepsy, pregabalin is likely to be more effective than gabapentin at comparable effective doses, based on clinical response and the number of SFD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.